Cara Therapeutics ( (TVRD) ) has released its Q1 earnings. Here is a breakdown of the information Cara Therapeutics presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Tvardi Therapeutics, Inc., formerly known as Cara Therapeutics, is a clinical-stage biopharmaceutical company focused on developing novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. The company recently completed a merger with Legacy Tvardi, resulting in a name change and a reverse stock split.
In the latest earnings report, Tvardi Therapeutics reported a net loss of $4.9 million for the quarter ending March 31, 2025, compared to a net loss of $30.7 million in the same period the previous year. The company’s revenue increased to $2.6 million from $2.1 million, driven by collaborative and other revenue streams. Despite the increase in revenue, the company continues to face significant operating expenses, primarily in research and development and general administrative costs.
Key financial metrics indicate that Tvardi Therapeutics has cash and cash equivalents of $34.2 million, down from $37.9 million at the end of 2024. The company’s liabilities related to sales of future royalties and milestones increased to $45.8 million. The merger with Legacy Tvardi is expected to strengthen the company’s pipeline, particularly with its lead product candidate, TTI-101, which is in Phase 2 clinical development.
Looking forward, Tvardi Therapeutics plans to continue investing in its research and development activities, with a focus on advancing its STAT3 inhibitors. The company acknowledges the need for additional funding to support its operations and achieve its strategic objectives. Management remains committed to exploring various financing options to ensure the company’s long-term sustainability and growth.